LifeArc appoints Dr Linda Bradley to head up business development

LifeArc announces that Dr Linda Bradley has joined as our new Head of Business Development, effective immediately.

In this newly-created role, Linda will be responsible for leading LifeArc’s commercial partnerships and alliance management activities, shaping the delivery of business development to ensure that assets partnered, created or developed by LifeArc will have the best chance of success to reach patients. Linda will be reporting into LifeArc’s Chief Business Officer, Dr Ian Campbell, who himself joined the charity at the end of 2020.

Commenting on Linda’s appointment, Dr Campbell said: “LifeArc plays a vital role in advancing medical research by providing the funds, advice and scientific expertise to translate early stage innovation. Linda joins us at an exciting time as we look to raise awareness of our capabilities and develop strategic partnerships with the biopharma industry, and medtech and technology companies. Her experience and skills will ensure proactive management of our assets, contributing to our ability to create long-term impact for patients and sustainability for the charity.”

Linda joins LifeArc from GlaxoSmithKline’s Worldwide Business Development team, bringing over 25 years of business development experience in the pharmaceutical industry. She has a strong track record of leading teams to in-license, divest and establish collaborative alliances for both technology platforms and development assets, and a demonstrated ability to meet strategic and financial goals. Linda has worked and led teams in both the US and UK, and has led deals in Asia, US, and Europe. Linda has a scientific background in genetics and a PhD in molecular immunology.